Creating new medications to help manage opioid use disorder
Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder
This study is looking at new ways to help people with opioid use disorder by creating a treatment that can lessen the effects of opioids without completely blocking them, which could make it easier for patients to stick to their recovery plan and stay safe.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eleven Therapeutics Corp NIH-funded |
| Lab location | 1 site (Encintias, United States) |
| Project ID | NIH-10918505 on NIH RePORTER |
What this research studies
This research focuses on developing new treatments for opioid use disorder (OUD) by creating negative allosteric modulators (NAMs) of the mu-opioid receptor. These NAMs are designed to reduce the effects of opioid agonists without completely blocking the receptor, which may help patients avoid withdrawal symptoms and reduce the risk of overdose. The approach aims to improve patient compliance and effectiveness compared to existing treatments like buprenorphine and methadone. By targeting the mu-opioid receptor in a novel way, the research seeks to provide a safer and more effective option for individuals struggling with OUD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with opioid use disorder who are seeking alternative treatment options.
Not a fit: Patients who are not struggling with opioid use disorder or those who have not responded to previous treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for patients with opioid use disorder, reducing the risk of overdose and improving treatment compliance.
How similar studies have performed: While the approach of using negative allosteric modulators is relatively novel, there is ongoing interest in developing alternative treatments for opioid use disorder, indicating potential for success.
Where this research is happening
Encintias, United States
- Eleven Therapeutics Corp — Encintias, United States (Active)
Researchers
- Principal investigator: Traynor, John R. — Eleven Therapeutics Corp
- Study coordinator: Traynor, John R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.